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1 
USE OF MODIFIED PYRIMIDINE 
COMPOUNDS TO PROMOTE STEM CELL 
MIGRATION AND PROLIFERATION 
2 
While the synaptic connections involved in neural circuits 
are continuously altered throughout the life of the individual, 
due to synaptic plasticity and cell death, neurogenesis (the 
generation of new neurons) was thought to be complete early 
in the postnatal period. The discovery ofMNSCs in the adult 
brain (see, e.g., Alvarez-Buylla et al., 1997, J. Neurabial. 33: 
585-601; Gould et al., 1999, Science 286: 548-552) has sig-
nificantly changed the theory on neurogenesis, as the pres-
ence of MNSCs in the adult brain suggests that regeneration 
This application is related to U.S. Provisional Patent Appli-
cation, Ser. No. 60/348,473, filed Jan. 14, 2002, and Ser. No. 
60/357,783, filed Feb. 19, 2002, and Ser. No. 60/376,257, 
filed Apr. 29, 2002, and Ser. No. 60/381,138, filed May 8, 
2002, and Ser. No. 60/404,361, filed Aug. 19, 2002, and Ser. 
No. 60/430,381, filed Dec. 2, 2002, the disclosures of each of 
which are expressly incorporated by reference herein. 
This invention was made with support from the U.S. Gov-
ermnent through the National Institutes of Health, grant no. 
R03-AG 19874. The govermnent has certain rights in this 
invention. 
10 of neurons can occur throughout life. Nevertheless, age, 
physical and biological trauma or neurodegenerative disease-
associated loss of brain function, herein referred to as a "neu-
rological deficit," can far outweigh any potential restorative 
effects due to endogenous neurogenesis. As a result, up-
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
15 regulated or stimulated proliferation of endogenous MNSCs 
as well as transplantation ofMNSCs are potentially valuable 
treatments for those suffering from the loss of, or loss of 
appropriate, brain function due to age, physical and biologi-
cal trauma or neurodegenerative disease (i.e., a neurological 
This invention relates to methods for stimulating prolifera-
tion and migration of mammalian stem cells in vivo and in 
vitro and cells produced by those methods. In particular, the 
invention provides reagents and methods for efficiently pro-
liferating stem cells in an animal in need thereof and produc-
ing stem cells that can be re-introduced into an animal in need 
thereof to alleviate neurological and corporal disorders. 
20 deficit). No such treatments are known in the art. 
Due to the advancing average age of the population, and 
concomitantly increased incidence of neurological deficit 
that accompanies advancing age, treatment of neurodegen-
erative diseases has become a major concern. Such diseases, 
2. Background of the Related Art 
25 including Alzheimer's disease, Huntington's chorea and Par-
kinson's disease, have been linked to neuronal degeneration 
at specific locations in the brain leading to the inability of the 
brain region to synthesize and release neurotransmitters that 
Stem cells are often defined as self-renewing and multipo-
tent, with the ability to generate diverse types of differentiated 30 
cells. As such, they show promise in the treatment of neuro-
logical and corporal disorders (also referred to as neurologi-
are vital to neuronal signaling. 
Neurodegeneration also encompasses many conditions 
and diseases, age-related or not, that result in neuronal loss. 
These conditions include CNS trauma, such as ischemia 
(stroke) and epilepsy, as well as diseases that result in neu-
ronal loss, including amyotrophic lateral sclerosis and cere-
cal and corporal "deficits"), or any loss or diminishment of 
tissue function due to age, disease, trauma or other factor. 
However, such treatments have faced significant hurdles that 
have yet to be substantially overcome. 
35 bra! palsy. 
NSCs and Neurological Deficits 
Many such neurological deficits are localized to particular 
regions of the brain. Degeneration in a brain region known as 
the basal ganglia can lead to diseases with varied and different 
cognitive and motor symptoms, depending on the exact loca-
40 ti on of the lesion. The basal ganglia consists of many separate 
regions, including the striatum (which consists of the caudate 
and putamen), the globus pallidus, the substantia nigra, sub-
stantia innominata, ventral pallidum, nucleus basalis ofMey-
Because an important focus of stem cell replacement thera-
pies has been neurological disorders, neural stem cells, and 
particularly fetal neural stem cells, have been a major 
research target. During development of the central nervous 
system (CNS), multipotent neural stem cells (MNSCs), also 
known as multi potent precursor cells (MPCs ), or tissue-spe-
cific neural stem cells (NSCs), proliferate, giving rise to tran- 45 
siently dividing progenitor cells that eventually differentiate 
into the cell types that compose the adult brain, including 
neurons, astrocytes and oligodendrocytes. NSCs have been 
isolated from several mammalian species, including mice, 
rats, pigs and humans. See, e.g., International Application, 50 
Publication Nos. WO 93/01275, WO 94/09119, WO 
94/10292, WO 94/16718 and Cattaneo et al., 1996, Mal. 
Brain Res. 42: 161-66. NSCs from the embryonic and adult 
rodent central nervous system (CNS) have been isolated and 
further propagated in vitro in a variety of culture systems. 55 
See, e.g., Frolichsthal-Schoelleret al., 1999, NeuraRepart 10: 
345-351; Doetsch et al., 1999, Cell 97: 703-716. NSCs from 
the human fetal brain have been cultured using serum-free 
medium supplemented with epidermal growth factor (EGF) 
and/or basic fibroblast growth factor (bFGF). See, e.g., 60 
Svendsen et al., 1998, J. Neurasci. Meth. 85: 141-152; Car-
penter et al., 1999, Exp. Neural. 158: 265-278. NSCs cultured 
utilizing these serum-free, mitogen-supplemented methods 
generally form substantially undifferentiated, clustered 
aggregates. Upon removal of the mitogen( s) and provision of 
a substrate, these neural stem cells differentiate into neurons, 
astrocytes and oligodendrocytes. 
nert, ventral tegmental area and the subthalamic nucleus. 
Degeneration in the basal ganglia can lead to motor defi-
cits. For example, Huntington's chorea is associated with 
degeneration of neurons in the striatum, which leads to invol-
untary jerking movements. Degeneration of a small region 
called the subthalamic nucleus is associated with violent 
flinging movements of the extremities in a condition called 
ballismus, while degeneration in the putamen and globus 
pallidus are associated with a condition of slow writhing 
movements or athetosis. In Parkinson's disease, degeneration 
is seen in another area of the basal ganglia, the substantia 
nigra par compacta. This area normally sends dopaminergic 
connections to the dorsal striatum, which are important in 
regulating movement. Therapy for Parkinson's disease has 
centered upon restoring dopaminergic activity to this circuit. 
Alzheimer's disease patients exhibit a profound cellular 
degeneration of the forebrain and cerebral cortex. Further, a 
localized area of the basal ganglia, the nucleus basalis of 
Meynert, appears to be selectively degenerated. This nucleus 
normally sends cholinergic projections to the cerebral cortex 
that are thought to participate in cognitive functions including 
65 memory. 
The objective of most CNS therapies is to regain the par-
ticular chemical function or enzymatic activity lost due to 
US 7,687,505 B2 
3 
cellular degeneration. Administration of pharmaceutical 
compositions has been the main treatment for CNS dysfunc-
tion though this type of treatment has complications, includ-
ing the limited ability to transport drugs across the blood-
brain barrier, and drug-tolerance acquired by patients to 
whom these drugs are administered for long periods. 
Transplantation of multipotent stem cells may avert the 
need not only for constant drug administration, but also for 
complicated drug delivery systems necessitated by the blood-
brain barrier. In practice, however, significant limitations 10 
have been found in this technique as well. First, cells used for 
transplantation that carry cell surface molecules of a differ-
entiated cell from a donor can induce an immune reaction in 
the recipient, a problem that is exacerbated by the physical 
damage caused by injection of cells directly into the affected 15 
area of the brain. In addition, the neural stem cells must be at 
a developmental stage where they are able to form normal 
neural connections with neighboring cells. 
4 
to gradually inactivate their transferred genes following 
transplantation and further may also not achieve normal neu-
ronal connections with the host tissue. 
Currently available transplantation approaches suffer from 
significant drawbacks. The inability in the prior art of the 
transplant to fully integrate into the host tissue, and the lack of 
availability of suitable cells in unlimited amounts from a 
reliable source for grafting are significant limitations ofneu-
rotransplantation. Studies utilizing intra-tissue injection of 
dissociated and partially differentiated NSCs have shown 
little promise (see, e.g., Benninger et al., 2000, Brain Pathol. 
10: 330-341; Blakemore et al. 2000, Cell Transplant 9: 289-
294; Rosser et al., 2000, Eur. J. Neurosci. 12: 2405-2413; 
Rubio et al., 2000, Mal. Cell Neurosci. 16: 1-13). The results 
have generally been poor because, among many consider-
ations, the dissociation of clusters ofNSCs is known to cause 
immediate senescence ofNSCs and increase the vulnerability 
ofNSCs in culture. See, e.g., Svendsen et al., 1998, J. Neu-
rosci. Meth. 85: 141-152. Further, regardless of adverse For these reasons, initial studies on neurotransplantation 
centered on the use of fetal cells. 
Mammalian fetal brain tissue has proven to have reasonable 
survival characteristics upon immediate transplantation. 
Increased survival capability of fetal neurons is thought to be 
due to the reduced susceptibility of fetal neurons to anoxia 
compared to adult neurons. An additional factor favoring 
survival of fetal cells is their lack of cell surface markers, 
whose presence may lead to rejection of grafted tissue from 
adults. However, although the brain is considered an immu-
nologically privileged site, some rejection of even fetal tissue 
can occur. Therefore, the ability to use heterologous fetal 
tissue is limited by tissue rejection and the resulting need for 
immunosuppressant drug administration. 
20 immune responses provoked by foreign tissue being intro-
duced into the brain, the trauma caused by the physical intro-
duction of cells directly into the damaged area can induce the 
recruitment of immune cells by the host that can eliminate the 
transplanted cells. Thus, significant problems with the use of 
25 NSCs to ameliorate neurological deficits remain. As 
described herein, neurological deficits also include non-brain 
tissues such as, for example, the eye and spinal cord. 
A "corporal deficit" is a disorder caused by a wide variety 
of diseases and injuries, resulting in trauma, malfunction, 
30 degeneration or loss of muscle such as, for example, cardiac 
muscle due to myocardial infarction. Other examples include 
malfunction, degeneration or loss of other cells and tissues 
apart from those discussed in the neurological deficit section 
above such as, for example, internal organs. For example, The use of large quantities of aborted fetal tissue presents 
other difficulties as well. Fetal CNS tissue is composed of 
more than one cell type, and thus is not a well-defined tissue 
source. In addition, it may be unlikely that an adequate and 
constant supply of fetal tissue would be available for trans-
plantation. For example, in the treatment of MPTP-induced 
Parkinsonism, tissue from as many as 6 to 8 fetuses can be 40 
required for successful implantation into the brain of a single 
patient. There is also the added problem of the potential for 
contamination during fetal tissue preparation. Since this tis-
sue may already be infected with a bacteria or virus, expen-
sive diagnostic testing is required for each fetus used. Even 
comprehensive diagnostic testing might not uncover all 
infected tissue. For example, there can be no guarantee that a 
sample is HIV-free, because antibodies to the virus are gen-
erally not present until several weeks after infection. 
35 liver function can be adversely affected by, among other 
things, disease (e.g., cirrhosis or hepatitis), trauma or age. The 
problems described above in using NSCs to remedy neuro-
logical deficits of the brain also apply to neurological deficits 
in other tissues, such as the eye, and corporal deficits. 
There exists a need in the art for improved methods for 
increasing the number of multi potent cells in an animal and 
thereby increasing the reservoir of remedial capacity con-
ferred by multipotent stem cells in tissues. There exists a need 
to stimulate proliferation, migration or both proliferation and 
45 migration of endogenous and exogenously introduced mam-
malian multipotent stem cells in vivo as well as manimalian 
multipotent stem cells in vitro. There exists a need for cells 
stimulated to proliferate, migrate or both proliferate and 
migrate, as well as pharmaceutical compositions for treating 
In addition to fetal tissue, there are other potential sources 50 a neurological deficit or corporal deficit comprising such 
stimulated cells. Further, there exists a need in the art for 
methods of administration of such cells stimulated to prolif-
erate, migrate or both proliferate and migrate and pharmaceu-
tical compositions thereof. Still further, there exists a need for 
of tissue for neurotransplantation, including cell lines and 
genetically engineered cell types, but both sources have seri-
ous limitations. Cell lines are immortalized cells that are 
derived, inter alia, by transformation of normal cells with an 
oncogene or by the culturing of cells in vitro with altered 
growth characteristics. Moreover, adverse immune response 
potential, the use of retroviruses to immortalize cells, the 
potential for the reversion of these cells to an amitotic state, 
and the lack of response by these cells to normal growth-
inhibiting signals make such cell lines sub-optimal for wide- 60 
spread use. 
55 methods for treating an animal having a neurological or cor-
poral deficit. 
Another approach to neurotransplantation involves the use 
of genetically engineered cell types or gene therapy. How-
ever, there still exists a risk of inducing an immune reaction 
with these cells. In addition, retrovirus mediated transfer may 65 
result in other cellular abnormalities. Also, cell lines pro-
duced by retrovirus-mediated gene transfer have been shown 
SUMMARY OF THE INVENTION 
This invention provides methods for stimulating prolifera-
tion, migration or both proliferation and migration of mam-
malian stem cells in vivo and in vitro and cells produced by 
those methods. In particular, the invention provides reagents 
and methods for efficiently proliferating stem cells in an 
animal in need thereof and producing stem cells that can be 
re-introduced into an animal in need thereof to alleviate neu-
rological disorders. 
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In a first aspect, the invention provides a method of stimu-
lating proliferation, migration or both proliferation and 
migration of endogenous and exogenous mammalian stem 
cells in vivo. In one embodiment, the method comprises the 
step of introducing to a mammal an effective amount of a 
pyrimidine derivative of: 
formula (I) 
R?:;i R2 Nr\X 
Rs-N y \__) 
N 
0 Ri 
or 
formula (II) 
where R1 to R8 independently represent a hydrogen atom, 
a lower alkyl group, CH3 0CH2CH2-, CH2CONH2 , 
-COCH3 , --COC2 H5 or -CH20COC2 H5 ; and X is NH, 
N-CH3 , N-C2H5 , N-ph, N--COOC2 H5 , N-S02CH3 , 
CH2 , CHCH3 , CHC2H5 , -0-or-S- in which ph stands 
for a phenyl group; or a pharmaceutically acceptable salt 
thereof. 
In another aspect, the invention provides a method of 
stimulating proliferation, migration or both proliferation and 
migration of exogenous mammalian stem cells in vivo to a 
mammal that has had more developmentally potent cells or 
the autologous stem cells or the non-autologous stem cells 
administered thereto. In one embodiment, the method com-
prises the step of introducing to a mammal an effective 
amount of the pyrimidine derivative of formulae (I) or (II) 
above or a pharmaceutically acceptable salt thereof. 
In another aspect, the invention provides a method of 
stimulating proliferation, migration or both proliferation and 
migration of endogenous mammalian stem cells in vitro. In 
one embodiment, the method comprises the step of contacting 
a mammalian stem cell with an effective amount of the pyri-
midine derivative of formulae (I) or (II) above or a pharma-
ceutically acceptable salt thereof. 
In another aspect, the invention provides a method for 
treating an animal with a neurological or corporal deficit. In 
one embodiment, the method comprises the step of adminis-
tering an effective amount of the pyrimidine derivative of 
formulae (I) or (II) above, or a pharmaceutically acceptable 
salt thereof, wherein the endogenous stem cell population is 
stimulated to proliferate and migrate to an area of tissue 
damage, differentiate in a tissue-specific manner and function 
in a manner that reduces the neurological or corporal deficit. 
In certain embodiments the inventive methods further com-
prise the step of administering more developmentally potent 
cells, wherein the more developmentally potent cells are 
stimulated to proliferate and migrate to an area of tissue 
damage, differentiate in a tissue-specific manner and function 
in a manner that reduces the neurological or corporal deficit. 
In related embodiments, the inventive method comprises 
administering autologous or non-autologous stem cells, 
6 
wherein the autologous or non-autologous stem cells are 
stimulated to proliferate and migrate to an area of tissue 
damage, differentiate in a tissue-specific manner and function 
in a manner that reduces the neurological or corporal deficit. 
In further related embodiments, the more developmentally 
potent cells or the autologous stem cells or the non-autolo-
gous stem cells administered with the pyrimidine derivative 
form a cluster of two or more cells. In further related embodi-
ments, the more developmentally potent cells or the autolo-
10 gous stem cells or the non-autologous stem cells are derived 
from a tissue or tissue-specific stem cell. In other embodi-
ments, the stem cell is a hematopoietic stem cell, a neural 
stem cell, an epithelial stem cell, an epidermal stem cell, a 
retinal stem cell, an adipose stem cell or a mesenchymal stem 
15 cell, any of which can be obtained from any tissue containing 
stem cells including but not limited to zygote, blastocyst, 
embryo, fetus, infant juvenile or adult, and optionally, a 
human species ofany of the preceding embodiments, whether 
naturally occurring or engineered. In certain embodiments, 
20 the cluster of two or more of the more developmentally potent 
cells or the autologous stem cells or the non-autologous stem 
cells comprises less than about 50 percent redifferentiated 
cells, or more preferably less than about 25 percent rediffer-
entiated cells, or even more preferably less than about 10 
25 percent redifferentiated cells, or even more preferably less 
than about 5 percent redifferentiated cells, or even more pref-
erably less than about 1 percent redifferentiated cells. In 
related embodiments, the more developmentally potent cells 
or the autologous stem cells or the non-autologous stem cells, 
30 in the form of a cluster of two or more cells in other related 
embodiments, are administered by injecting the more devel-
opmentally potent cells with a syringe, inserting the more 
developmentally potent cells or the autologous stem cells or 
the non-autologous stem cells with a catheter or surgically 
35 implanting the said cells. In other, further related embodi-
ments, the more developmentally potent cells or the autolo-
gous stem cells or the non-autologous stem cells are injected 
with a syringe, inserted with a catheter or surgically 
implanted either to a body cavity that is fluidly-connected to 
40 the area of neurological or corporal deficit or to the area of 
neurological or corporal deficit. In embodiments relating to 
neurological or corporal deficits, the neurological deficit is 
optionally caused by a neurodegenerative disease, a traumatic 
injury, a neurotoxic injury, ischemia, a developmental disor-
45 der, a disorder affecting vision, an injury or disease of the 
spinal cord, a demyelinating disease, an autoimmune disease, 
an infection, or an inflammatory disease and the corporal 
deficit is optionally caused by corporal disease, disorder, 
injury, trauma, malfunction, degeneration or loss 
50 In certain embodiments the pyrimidine derivative of for-
mula (I) is MS-818, or 2-piperadino-6-methyl-5-oxo-5, 6-di-
hydro(7H) pyrrolo[2,3-d]pyrimidine maleate (the C4 H4 0 4 
maleate salt), as disclosed in U.S. Pat. No. 4,959,368, incor-
porated by reference herein. In certain in vivo embodiments, 
55 the pyrimidine derivatives of formulae (I) and (II) is admin-
istered at a concentration of between about 0.01 mg/kg/day to 
50 mg/kg/day, more preferably between about 0.1 mg/kg/day 
to 10 mg/kg/day, even more preferably between about 1 
mg/kg/day to 5 mg/kg/day, and even more preferably about 3 
60 mg/kg/day. In these embodiments, the pyrimidine derivatives 
of formulae (I) and (II) is administered for between about 1 
and 60 days, or more preferably between about 1 and 30 days, 
or more preferably between about 1 and 15 days, or even more 
preferably between about 1 and 10 days, or more preferably 
65 between about 2 and 7 days, or even more preferably about 5 
days. In certain others of these embodiments, the methods 
further comprise the step of administering a growth factor. In 
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certain embodiments, the growth factor comprises fibroblast 
growth factor, epidermal growth factor or a combination 
thereof. 
In certain in vitro embodiments, the stem cell culture is 
contacted with the pyrimidine derivative of formulae (I) or 5 
(II) in an effective amount, or a concentration of between 
about 50 nM to 1 mM, or more preferably between about 500 
nM to 500 µM, or even more preferably between about 1 µM 
to 100 µM, or more preferably between about 5 µM to 7 5 µM 
and even more preferably about 50 µM. In these embodi- 10 
ments, the stem cell culture is contacted with pyrimidine 
derivatives of formulae (I) and (II) for an effective period, or 
between about 1 and 60 days, or more preferably between 
about 1 and 30 days, or more preferably between about 1 and 
15 days, or even more preferably between about 1 and 10 15 
days, or more preferably between about 2 and 7 days, or even 
more preferably about 5 days. In certain others of these 
embodiments, the methods further comprise the step of con-
tacting the cell culture with a growth factor. In certain 
embodiments, the growth factor comprises fibroblast growth 20 
factor, epidermal growth factor or a combination thereof. In 
certain others of these embodiments, the methods further 
comprise contacting the stem cell culture with heparin. 
In another aspect, the invention provides cells stimulated 
for proliferation, migration or both proliferation and migra- 25 
ti on produced according to the methods of the invention. In 
another aspect, the invention provides a pharmaceutical com-
position for treating a neurological or corporal deficit com-
prising the cells stimulated for proliferation, migration or 
both proliferation and migration produced according to the 30 
methods of the invention. In certain embodiments, the phar-
maceutical composition further comprises a pharmaceuti-
cally acceptable carrier. 
Thus, the invention advantageously provides methods of 
stimulating proliferation and migration of mammalian stem 35 
cells in vivo and in vitro, cells produced by those methods, 
pharmaceutical compositions to treat neurological and cor-
poral deficits, and methods of administering the cells and 
pharmaceutical compositions of the invention. 
Specific embodiments of the present invention will become 40 
evident from the following more detailed description of cer-
tain preferred embodiments and the claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
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FIG. 2 shows typical fluorescent immunohistochemical 
photomicrographs of aged rat brain 30 days after transplan-
tation ofMNSCs of the co-owned and co-pending U.S. patent 
application referenced above. bIII-tubulin and GFAP immu-
noreactivity were used as markers for neuron and glia, respec-
tively. (a) MNSCs of the co-owned and co-pending U.S. 
patent application migrated into the cortex and differentiated 
into neurons as indicated by the bIII-tubulin positive cells 
(green), which have morphologies typical of pyramidal cells 
in layer IV and V of the parietal cortex. Apical dendrites were 
pointed towards to the edge of the cortex. Since the NSCs 
were pre-treated with BrdU, the transplanted cells have BrdU 
positive nuclei (red). Contrarily, the host cell's nuclei are 
counter stained with DAPI (blue). Many cells having BrdU 
positive nuclei are observed with bIII-tubulin immunoreac-
tivity in layer II and without bIII-tubulin immunoreactivity in 
layer III. (b, c) Higher magnification of the parietal cortex in 
cortex layer IV: all the bIII-tubulin immunoreactive (green) 
positive cells show BrdU (red) positive nuclei while many 
other host cell's nuclei are stained with only DAPI (blue). (d) 
MNSCs according to said co-owned and co-pending U.S. 
patent application migrated into the hippocampus and differ-
entiated into bIII-tubulin positive cells (green), in CAI pyra-
midal cell layer. These bIII-tubulin positive cells have BrdU 
positive nuclei (red), indicating that these cells originated 
from transplanted cells. In contrast, host cell nuclei counter 
stained with DAPI (blue) are not bIII-tubulin positive. (e) In 
the dentate gyrus many fibers were bIII-tubulin positive in 
addition to the bIII-tubulin positive cells (green) and GFAP 
positive sells (red). (f) bIII-tubulin positive cells (green) and 
GFAP positive cells (red) were found in layer IV and layer III, 
respectively. Such a layer of astrocytes was not observed in 
normal rats without NSC transplantation. Again, the methods 
of the instant invention can act to increase the number of such 
exogenously transplanted, BrdU-treated cells in vivo, as well 
as enhance their number while being treated according to the 
methods of the co-owned and co-pending application. The 
methods of the instant invention can also increase the abun-
dance of the endogenous NSC population. 
FIG. 3 shows the effects ofMS-818 on endogenous neural 
45 stem cell populations in the brain. (a) Typical immunohis-
tochemistry (x200) using BrdU (brown, marker for prolifer-
ating cells) in a control aged rat cerebral cortex without 
MS-818 treatment. (b) Typical immunohistochemistry 
(x200) using BrdU in an aged rat cerebral cortex with 
FIG. 1 shows the effect of transplantation of MNSC 
according to the methods of co-owned and co-pending U.S. 
patent application, entitled "Novel Mammalian Multipotent 
Stem Cells and Compositions, Methods of Preparation and 
Methods of Administration Thereof," (Ser. No. 10/345,126, 
filed Jan. 14, 2003) on memory score in the Morris water 
maze test. (a) Individual memory score before and after trans-
plantation shows improvement in the majority of the animals. 
Blue: Aged memory impaired animals, Green: Aged memory 
unimpaired animals, Red: Matured animals. (b) Mean of 
memory score in each animal group before (narrow striped 
bar) and after (black bar) SC transplantation shows a signifi-
cant improvement in aged memory impaired and young ani-
mals. The animals that received vehicle injection do not show 
significant difference in memory score between before (wide 
striped bar) and after (hatched) the injection. The methods of 
the instant invention can act to increase the number of such 
exogenously transplanted cells in vivo, as well as enhance 
their number while being treated according to the methods of 
said co-owned and co-pending application. Further, the meth- 65 
ods of the instant invention can increase the abundance of the 
endogenous NSC population. 
50 MS-818 treatment (3 mg/kg/day, i.p. for 5 days). The number 
ofBrdU positive cells is significantly increased after MS-818 
treatment. (c) Typical immunohistochemistry (x200) using 
BrdU (brown, marker for proliferating cells) in a control aged 
rat SVZ without MS-818 treatment. (d) Typical immunohis-
55 tochemistry (x200) using BrdU in an aged rat SVZ with 
MS-818 treatment (3 mg/kg/day, i.p. for 5 days). The number 
of BrdU positive cells is increased after MS-818 treatment. 
(e) Quantitative analysis of the effects ofMS-818 on a num-
ber of BrdU-positive cells in the cortex (a, b ). There was a 
60 7-fold increase in stem cell population after MS-818 treat-
ment. 
FIG. 4 shows the effects ofMS-818 on endogenous retinal 
stem cell populations. (a) Typical immunohistochemistry 
(x400) using BrdU (red, marker for proliferating cells) in 
control rat retina without MS-818 treatment. (b) Typical 
immunohistochemistry (x400) using BrdU in rat retina with 
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filed Jan. 14, 2003, or "App. 2." Each application is incorpo-
rated herein by reference in their entirety. 
intraocular administration of MS-818 (10 µg/20 µ!). The 
number of BrdU-positive cells is clearly increased after the 
treatment. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
As used herein, the term "cluster" refers to a group of two 
or more non-terminally differentiated cells. A cluster can 
5 comprise the progeny of a single multipotent stem cell or 
small cluster of primary cells. 
As used herein, the terms "effective amount" and "thera-
peutically effective amount" each refer to the amount of 
reagent used to support or produce the desired activity. In the 
This invention provides methods for stimulating prolifera-
tion, migration or proliferation and migration of endogenous 
and exogenous mammalian stem cells in vivo. The invention 
also provides methods for stimulating proliferation, migra-
tion or proliferation and migration of mammalian stem cells 
in vitro. The method further provides cells produced by the 
aforementioned methods. More generally, the invention pro-
vides reagents and methods for efficiently proliferating mam-
malian stem cells in an animal in need thereof and producing 
stem cells that can be re-introduced into an animal in need 
thereof to alleviate neurological and corporal disorders. 
10 case of the cells stimulated for proliferation, migration or 
both proliferation and migration prepared and delivered 
according to the invention, an effective amount is an amount 
necessary to support or produce an observable level of one or 
more biological activities of MSC as set forth herein. Regard-
15 ing pyrimidine derivatives, an effective amount can be 
between about 0.01 mg/kg/day to 50 mg/kg/day, more pref-
erably between about 0.1 mg/kg/day to 10 mg/kg/day, even 
more preferably between about 1 mg/kg/day to 5 mg/kg/day, 
and even more preferably about 3 mg/kg/day. 
An "effective period" as used herein refers to the time 
period necessary for the reagents and cells of the invention to 
accomplish their specified activities. For example, cells of the 
invention can be contacted with a pyrimidine derivative for an 
effective period to make them more developmentally potent. 
As used herein, the terms "multipotent neural stem cells 
(MNSCs ),""neural stem cells (NSCs ),"and "multi potent pre- 20 
cursor cells (MPCs)" refer to undifferentiated, multipotent 
cells of the CNS. Such terms are commonly used in the 
scientific literature. MNSCs can differentiate into tissue-spe-
cific cell types, for example astrocytes, oligodendrocytes, and 
neurons when transplanted in the brain. The multipotent cells 25 An effective period for contact with a pyrimidine derivatives 
can be, for example, between about 1 and 60 days, or more 
preferably between about 1 and 30 days, or more preferably 
between about 1 and 15 days, or even more preferably 
between about 1 and 10 days, or more preferably between 
of the invention are distinguished from natural NSCs by their 
stimulation for proliferation, migration or both proliferation 
and migration due to treatment by the methods of the inven-
tion. 
As used herein, a "less developmentally potent cell" is a 
cell that is capable oflimited multi-lineage differentiation or 
capable of single-lineage, tissue-specific differentiation, for 
example, an untreated mesenchymal stem cell can differen-
tiate into, inter alia, osteocytes and chrondrocytes, i.e., cells 
of mesenchymal lineage but has only limited ability to differ-
entiate into cells of other lineages (e.g., neural lineage.). 
30 about 2 and 7 days, or even more preferably about 5 days. 
The term "pharmaceutically acceptable carrier" or "physi-
ologically acceptable carrier" as used herein refers to one or 
more formulation materials suitable for accomplishing or 
enhancing the successful delivery of the pharmaceutical com-
35 position of stimulated stem cells prepared and delivered 
according to the invention. 
As used herein, a "more developmentally potent cell" is a 
cell that is readily capable of differentiating into a greater 
variety of cell types than its corresponding less developmen-
tally potent cell. For example, a mesenchymal stem cell can 40 
readily differentiate into osteocytes and chrondrocytes but 
has only limited ability to differentiate into neural or retinal 
lineage cells (i.e., it is a less developmentally potent cell in 
this context). Mesenchymal stem cells treated according to 
the methods of the above-referenced co-owned and co-pend- 45 
ing U.S. patent application become more developmentally 
potent because they can readily differentiate into, for 
example, mesenchymal-lineage and neural-lineage cell 
types; the plasticity of the cells is increased when treated 
according to the methods of the invention. 50 
"More developmentally potent cell" and "less develop-
mentally potent cell" as used herein are fully disclosed and 
claimed in co-owned and co-pending U.S. patent application 
entitled "Novel Mammalian Multipotent Stem Cells and 
Compositions, Methods of Preparation and Methods of 55 
Administration Thereof," Ser. No. 10/345,126, filed Jan. 14, 
2003, or "App. 1." 
As used herein, "multipotent stem cells" or "MSCs" refer 
to the cells prepared according to the methods disclosed 
herein and in co-owned and co-pending U.S. patent applica- 60 
tion entitled "Novel Mammalian Multipotent Stem Cells and 
Compositions, Methods of Preparation and Methods of 
Administration Thereof," Ser. No. 10/345,126, filed Jan. 14, 
2003, or "App. 1" and co-owned and co-pending U.S. patent 
application entitled "Novel Mammalian Multipotent Neural 65 
Stem Cells and Compositions, Methods of Preparation and 
Methods of Administration Thereof," Ser. No. 10/345,126, 
As disclosed in further detail herein, the inventive methods 
provide for introducing pyrimidine derivatives of formulae (I) 
or (II), 
R,-:~'(8X 
(I) 
~ 
(II) 
~5 /\ 
0
==<N-YNYN\___Jx 
)(JN 
Ri; R1 Rs 
where R1 to R8 independently represent a hydrogen atom, 
a lower alkyl group, CH30CH2 CH2-, CH2CONH2 , 
--COCH3 , --COC2 H5 or -CH20COC2 H5 ; and X is NH, 
N--CH3 , N-C2 H5 , N-ph, N--COOC2 H5N-S02CH3 , 
CH2 , CHCH3 , CHC2H5 , ---0- or-S- in which ph stands 
for a phenyl group; or a pharmaceutically acceptable salt 
thereof, to a mammal in an amount effective to stimulate 
proliferation, migration or both proliferation and migration of 
endogenous multi potent stem cells in vivo. Endogenous mu!-
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ti potent stem cells can be of varied origin, inter alia, stem cells 
of hematopoietic, neural, mesenchymal, epithelial, epider-
mal, adipose and retinal origin, and administration of the 
pyrimidine derivatives can be localized to a particular tissue. 
The invention also provides methods for introducing pyri-
midine derivatives, or pharmaceutically suitable salts thereof, 
to a mammal in an amount effective to stimulate proliferation, 
migration or both proliferation and migration, in vivo, of 
exogenous multipotent stem cells introduced to the mammal 
before, after or concurrently with the pyrimidine derivative. 
Further, a rest period between the introduction of the pyrimi-
dine derivative and the multipotent stem cells can be imple-
mented as necessary to minimize any trauma caused by their 
administration. The exogenously introduced multipotent 
stem cells can be prepared according to the methods 
described in App. 1 or App. 2, and as set forth below. 
Both the pyrimidine derivatives and the exogenous multi-
potent stem cells can be administered by injection with a 
syringe, insertion with a catheter or surgical implantation. 
The pyrimidine derivatives can be administered at the site of 
neurological or corporal deficit, systemically (e.g., intrave-
nously), or in the case of neurological deficits of the brain, 
spinal cord or any tissues accessible by cerebral spinal fluid 
(CSF), in a brain ventricle. The exogenous multipotent stem 
cells can be administered at the site of neurological or corpo-
ral deficit, systemically (e.g., intravenously), or in the case of 
neurological deficits of the brain, spinal cord or any tissues 
accessible by cerebral spinal fluid (CSF), in a brain ventricle. 
12 
capable of naturally responding to. Thus, hematopoietic stem 
cells administered to a skin wound with pyrimidine derivative 
proliferate and migrate due to the exposure to the pyrimidine 
derivative and differentiate according to the environmental 
signals they encounter in the wound and are capable of 
responding to. Immunosuppressant drugs can be used to sup-
press any immunorejection of non-autologous cells. Simi-
larly, mesenchymal stem cells can be isolated from an animal 
in need of additional mesenchymal stem cells. Limited num-
10 bers of cells can be isolated and treated with pyrimidine 
derivatives according to the methods of the invention. Such 
cells can be stimulated to proliferation, migration or both due 
to exposure to the pyrimidine derivative. Large numbers of 
cells can be propagated in vitro and reintroduced to the donor 
15 or other, non-autologous recipient. 
The multi potent stem cells can be administered in the form 
a cluster of two or more cells. The multipotent stem cells can 
be derived from a tissue or tissue-specific stem cell, for 
example, a hematopoietic stem cell, a neural stem cell, an 
20 epithelial stem cell, an epidermal stem cell, a retinal stem cell, 
an adipose stem cell and a mesenchymal stem cell, any of 
which can be obtained from any tissue containing stem cells 
including but not limited to zygote, blastocyst, embryo, fetus, 
infant juvenile or adult, and optionally, a human species of 
25 any of the preceding embodiments, whether naturally occur-
ring or engineered. 
When utilizing "more developmentally potent" multipo-
tent stem cells or autologous stem cells or non-autologous 
stem cells in a cluster of two or more cells, the cluster of 
30 multipotent stem cells can comprise less than about 50 per-
cent redifferentiated cells, or more preferably less than about 
25 percent redifferentiated cells, or even more preferably less 
than about 10 percent redifferentiated cells, or even more 
preferably less than about 5 percent redifferentiated cells, or 
In another in vivo embodiment, the invention provides a 
method for treating an animal with a neurological or corporal 
deficit. In one embodiment, the method can comprise admin-
istering an effective amount of a pyrimidine derivative or 
pharmaceutically acceptable salt thereof such that the endog-
enous stem cell population is stimulated to proliferate and 
migrate to an area of tissue damage, differentiate in a tissue-
specific manner and function in a manner that reduces the 
neurological or corporal deficit. In other embodiments, the 
inventive method further comprises the step of administering 
multipotent stem cells of App. 1 or App. 2, referenced above, 
wherein the exogenous multipotent stem cells are stimulated 40 
to proliferate and migrate to an area of tissue damage, differ-
entiate in a tissue-specific manner and function in a manner 
that reduces the neurological or corporal deficit. Similarly, in 
related embodiments, the inventive method can comprises 
administering autologous or non-autologous stem cells 
instead of administering the multi potent stem cells of App. 1 
35 even more preferably less than about 1 percent redifferenti-
ated cells. "Redifferentiated cells" as used herein, refers to 
cells that have terminally differentiated during the perfor-
mance of the methods herein prior to migration, differentia-
tion and incorporation into host tissue to. 
Similar to other embodiments described above, the multi-
potent stem cells, optionally in cluster form, are administered 
by injecting with a syringe, inserting with a catheter or 
implanting surgically. The multipotent stem cells can be 
administered at the site of neurological or corporal deficit, 
45 systemically (e.g., intravenously), or in the case of neurologi-
cal deficits of the brain, spinal cord or any tissues accessible 
by cerebral spinal fluid (CSF), in a brain ventricle. In other 
words, the cells can be implanted to a body cavity that is 
fluidly-connected to the area of neurological or corporal defi-
or App. 2, wherein the autologous or non-autologous stem 
cells are stimulated to proliferate and migrate to an area of 
tissue damage, differentiate in a tissue-specific manner and 
function in a manner that reduces the neurological or corporal 
deficit. As an example, tissue-specific stem cells can be iso-
lated from the eventual recipient or another source, and 
administered with the pyrimidine derivative. The isolated 
cells can be treated in vitro with the pyrimidine derivative or 
be left untreated with the pyrimidine derivative. When the 
autologous or non-autologous stem cells are administered to 
the human or animal with a neurological or corporal deficit, 
the cells differentiate in a tissue-specific manner according to 
their natural potency. For example, hematopoietic stem cells 
have some natural, limited capacity to differentiate into cer-
tain skin cells. According to this embodiment, hematopoietic 
stem cells could be isolated from the recipient of another 
source and treated before, concurrently, or after administra-
tion to the recipient with a pyrimidine derivative. Such cells 
are stimulated for proliferation, migration or both prolifera-
tion and migration, and differentiate according to the envi-
ronmental signals they (1) actually encounter and (2) are 
50 cit or directly to the area of neurological or corporal deficit. 
The neurological deficit is optionally caused by a neurode-
generative disease, a traumatic injury, a neurotoxic injury, 
ischemia, a developmental disorder, a disorder affecting 
vision, an injury or disease of the spinal cord, a demyelinating 
55 disease, an autoimmune disease, an infection, or an inflam-
matory disease and the corporal deficit is optionally caused 
by corporal disease, disorder, injury, trauma, malfunction, 
degeneration or loss. 
In the methods relating to the in vivo stimulation of prolif-
60 eration and migration of endogenous and exogenous mam-
malian stem cells, an effective amount of pyrimidine deriva-
tives is administered. An effective amount can be, for 
example, a concentration effective to accomplish aforemen-
tioned effects. Non-limiting, exemplary concentrations can 
65 be between about 0.01 mg/kg/day to 50 mg/kg/day, more 
preferably between about 0.1 mg/kg/day to 10 mg/kg/day, 
even more preferably between about 1 mg/kg/day to 5 mg/kg/ 
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day, and even more preferably about 3 mg/kg/day. The pyri-
midine derivatives can be administered as necessary to elicit 
the stimulatory effects, an effective period, which can be, for 
example, between about 1 and 60 days, or more preferably 
between about 1 and 30 days, or more preferably between 
about 1 and 15 days, or even more preferably between about 
1 and 10 days, or more preferably between about 2 and 7 days, 
or even more preferably about 5 days. 
14 
Pharmaceutical compositions optimally comprise a thera-
peutically effective amount of the stimulated cells of the 
invention in admixture with a pharmaceutically or physi-
ologically acceptable formulation agent selected for suitabil-
ity with the mode of administration. Acceptable formulation 
materials preferably are nontoxic to the stimulated cells and 
the recipients at the dosages and concentrations employed. 
The pharmaceutical compositions of the invention may 
contain formulation materials for modifying, maintaining, or The in vivo methods of the invention can further comprise 
the administration of a growth factor, including, for example, 
fibroblast growth factor (FGF), epidermal growth factor 
(EGF) or a combination thereof. 
10 preserving, for example, pH, osmolarity, viscosity, clarity, 
color, isotonicity, odor, sterility, stability, rate of dissolution 
or release, adsorption, or penetration of the composition, as 
well as proliferation, migration and differentiation capacity 
of the stimulated cells of the invention. Suitable formulation 
The invention also provides methods of stimulating prolif-
eration, migration or both proliferation and migration of 
mammalian stem cells in vitro. In one embodiment, the 15 
method comprises the step of contacting a mammalian stem 
cell or in vitro culture thereof with an effective amount of the 
pyrimidine derivative of formulae (I) or (II) above or a phar-
maceutically acceptable salt thereof. The stem cell culture 
can be contacted with the pyrimidine derivative at a concen- 20 
tration effective to produce the stimulatory effect. For 
example, a concentration of between about 50 nM to 1 mM 
can be used, or more preferably between about 500 nM to 500 
µM, or even more preferably between about 1 µM to 100 µM, 
or more preferably between about 5 µM to 75 µMand even 25 
more preferably about 50 µM. As with in vivo embodiments, 
the stem cell culture can be contacted with pyrimidine deriva-
tives for an effective period, which can be, for example, 
between about 1 and 60 days, or more preferably between 
about 1 and 30 days, or more preferably between about 1 and 30 
15 days, or even more preferably between about 1 and 10 
days, or more preferably between about 2 and 7 days, or even 
more preferably about 5 days. Also similar to the in vivo 
embodiments, the cell cultures can be contacted with a 
growth factor, for example, FGF, EGF or a combination 35 
thereof. A growth factor, as defined herein, refers to a protein, 
peptide or other molecule having a growth, proliferative, or 
trophic effect on the cells (whether "more" or "less" devel-
opmentally potent as defined herein) or progeny thereof. 
Growth factors used for inducing proliferation include any 40 
trophic factor that allows more or less developmentally potent 
cells to proliferate, including any molecule that binds to a 
receptor on the surface of the cell to exert a trophic, or growth-
inducing effect on the cell. Exemplary proliferation-inducing 
growth factors include epidermal growth factor (EGF), 45 
amphiregulin, acidic fibroblast growth factor (aFGF or FGF-
1), basic fibroblast growth factor (bFGF or FGF-2), trans-
forming growth factor alpha (TGFa), and combinations 
thereof. Preferred proliferation-inducing growth factors 
include EGF and FGF or a combination thereof. Growth 50 
factors are usually added to the culture medium at concentra-
tions of between about 1 fg/mL to 1 mg/mL. Concentrations 
between about 1 to 100 ng/mL are usually sufficient. Simple 
titration experiments routine in the art are used to determine 
the optimal concentration of a particular growth factor for a 55 
particular cell culture (see, e.g., Cutroneo et al., 2000, Wound 
Repair Regen, 8: 494-502). The method can, in certain 
embodiments, further comprise contacting the multipotent 
stem cell culture with heparin. 
The invention also provides cells that are treated according 60 
to the methods of the invention and are thereby stimulated to 
proliferate, migrate or both proliferate and migrate in vivo or 
in vitro. These cells can be used as an active ingredient in a 
pharmaceutical composition for treating a neurological defi-
cit or corporal deficit. In certain embodiments, the pharma- 65 
ceutical composition further comprises a pharmaceutically 
acceptable carrier as described below. 
materials include, but are not limited to, amino acids (such as 
glycine, glutamine, asparagine, arginine, or lysine), antimi-
crobial compounds, antioxidants (such as ascorbic acid, 
sodium sulfite, or sodium hydrogen-sulfite), buffers (such as 
borate, bicarbonate, Tris-HCl, citrates, phosphates, or other 
organic acids), bulking agents (such as mannitol or glycine), 
chelating agents (such as ethylenediamine tetraacetic acid 
(EDTA)), complexing agents (such as caffeine, polyvinylpyr-
rolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclo-
dextrin), fillers, monosaccharides, disaccharides, and other 
carbohydrates (such as glucose, mannose, or dextrins), pro-
teins (such as serum albumin, gelatin, or immunoglobulins), 
coloring, flavoring and diluting agents, emulsifying agents, 
hydrophilic polymers (such as polyvinylpyrrolidone), low 
molecular weight polypeptides, salt-forming counterions 
(such as sodium), preservatives (such as benzalkonium chlo-
ride, benzoic acid, salicylic acid, thimerosal, phenethyl alco-
hol, methylparaben, propylparaben, chlorhexidine, sorbic 
acid, or hydrogen peroxide), solvents (such as glycerin, pro-
pylene glycol, or polyethylene glycol), sugar alcohols (such 
as mannitol or sorbitol), suspending agents, surfactants or 
wetting agents (such as pluronics; PEG; sorbitan esters; 
polysorbates such as polysorbate 20 or polysorbate 80; triton; 
trimethamine; lecithin; cholesterol or tyloxapal), stability 
enhancing agents (such as sucrose or sorbitol), tonicity 
enhancing agents (such as alkali metal halides-preferably 
sodium or potassium chloride--or mannitol sorbitol), deliv-
ery vehicles, diluents, excipients and/ or pharmaceutical adju-
vants. See REMINGTON'S PHARMACEUTICAL SCIENCES (18th Ed., A. 
R. Gennaro, ed., Mack Publishing Company 1990). 
The primary vehicle or carrier in a pharmaceutical compo-
sition may be either aqueous or non-aqueous in nature. For 
example, a suitable vehicle or carrier for injection may be 
water, physiological saline solution, or artificial cerebrospi-
nal fluid. Optimal pharmaceutical compositions will be deter-
mined by a skilled artisan depending upon, for example, the 
intended route of administration, delivery format, desired 
dosage and recipient tissue. See, e.g., REMINGTON'S PHARMA-
CEUTICAL SCIENCES, supra. Such compositions may influence 
the physical state, stability, and effectiveness of the compo-
sition. 
Examples of the pharmaceutically acceptable salts of the 
compounds of formulae (I) and (II) include hydrochlorides, 
hydrobromides, sulfates, bisulfites, phosphates, acidic phos-
phates, acetates, maleates, fumarates, succinates, lactates, 
tartrates, benzoates, citrates, gluconates, glucanates, meth-
anesulfonates, p-toluenesulfonates and naphthalene-sul-
fonates which are formed from acids capable of forming 
pharmaceutically acceptable anion-containing nontoxic acid 
addition salts, hydrates thereof, and quaternary ammonium 
(or amine) salts or hydrates thereof. In a preferred embodi-
ments the pyrimidine derivative of formula (I) is 2-pipera-
dino-6-methyl-5-oxo-5,6-dihydro(7H)pyrrolo[2,3-d]pyrimi-
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dine maleate (the C4H4 0 4 maleate salt), also known as 
MS-818 (see, for example, Sanyo et al., 1998, J. Neurosci 
Res. 54: 604-612). 
Thus, the invention advantageously provides methods of 
stimulating proliferation and migration of mammalian stem 
cells in vivo and in vitro, cells produced by those methods, 
pharmaceutical compositions to treat neurological and cor-
poral deficits, and methods of administering the cells and 
pharmaceutical compositions of the invention. 
Cells can be obtained in any way known in the art and from 
any tissue, for example, from donor tissue by dissociation of 
individual cells from the connecting extracellular matrix of 
the tissue or from commercial sources of NSCs (e.g., Bio-
Whittaker, Walkersville, Md., CC-2599). Tissue from brain 
can removed using sterile procedures, and the cells can be 
dissociated using any method known in the art including 
treatment with enzymes such as trypsin, collagenase and the 
like, or by using physical methods of dissociation such as 
mincing or treatment with a blunt instrument. Dissociation of 
neural cells can be carried out in tissue culture medium; in a 
preferred embodiment, the medium for dissociation of juve-
nile and adult cells is low calcium artificial cerebral spinal 
fluid (aCSF) having a formula identical to aCSF (124 mM 
NaCl, 5 mM KC!, 1.3 mM MgCl2 , 2 mM CaCl2 , 26 mM 
NaHC03 , and 10 mM D-glucose) except that MgCl2 is 
present at a concentration of3.2 mM and CaCl2 at a concen-
tration of 0.1 mM. Dissociated cells are centrifuged at low 
speed, between 200 and 2000 rpm, usually between 400 and 
800 rpm, the suspension medium is aspirated, and the cells are 
then resuspended in culture medium. Suspension cultures are 
preferred iflarge numbers of undifferentiated neural stem cell 
progeny are desired. Cell suspensions are seeded in any 
receptacle capable of sustaining cells, preferably culture 
plates or roller bottles that inhibit contact-dependent stem cell 
differentiation, including uncoated flask or a flask that has 
been treated to repel the cells. 
While isolation from brain tissue is generally feasible for 
preparation of exogenous multipotent cells to be adminis-
tered with the pyrimidine derivative according to the methods 
of the instant invention, stem cells from bone marrow (e.g., 
mesenchymal stem cells) are a particularly good source of 
cells for generating multi potent stem cells of App. 1, because 
isolation techniques are well established in the art having 
been used for decades in immune disorder bone marrow 
transplants. Further, the methods of the instant invention can 
then be carried out with autologous cells, thus alleviating any 
concerns over immunological rejection. Thus, a patient's own 
mesenchymal stem cells can be isolated, treated according to 
the methods of App. 1 andreadministered where necessary. In 
contrast, autologous transplants using a neural cell source, 
while certainly not impossible, are not as feasible as, for 
example, mesenchymal cells. 
Growth of multipotent stem cells under the above culture 
conditions induces or permits these cells to form undifferen-
tiated cell clusters. These clusters are optimally grown at a 
density ofapproximately 50 clusters per T75 flask in 20 mL of 
the growth medium consisting of, for example, DMEM/ 
HAMS F12 (at about 3:1; Gibco, BRL, Burlington, ON), 
supplemented with an antibiotic-antimycotic mixture (1: 100, 
penicillin G, streptomycin sulfate, amphotericin B; Gibco ), 
B27 (1:50, GIBCO), human recombinant FGF-2 andEGF (20 
ng/ml each, R&D Systems, Minneapolis, Minn.) and heparin 
(5 µg/mL, Sigma, St. Louis, Mo.). The cultures are kept in a 
C02 incubator (about 5% C02 ) at 3 7° C. To facilitate optimal 
growth conditions, clusters of two or more cells are sectioned 
into quarters approximately every 14 days and fed by replac-
ing 50% of the medium approximately every 4-5 days. These 
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conditions permit rapid and continual growth of MSCs that 
can be expanded indefinitely while retaining their multi potent 
character. As with most eukaryotic cells, conditions for cul-
turing should be as close as possible to physiological condi-
tions. The pH of the culture medium should be close to 
physiological pH, preferably between pH 6-8, more prefer-
ably between about pH 7 to 7.8, with pH 7.4 being most 
preferred. Physiological temperatures range between about 
30° C. to 40° C. Cells are preferably cultured at temperatures 
10 between about 32° C. to about 38° C., and more preferably 
between about 35° C. to about 37° C. Multipotentneural stem 
cells (MNSCs) prepared and maintained as disclosed herein 
continue to exhibit multipotent character after more than 
three years of serum-free propagation. Treatment with pyri-
15 midine derivative according to the methods of the invention 
then transform these cells into the cells of the invention, cells 
specially stimulated for proliferation, migration or both. If in 
vitro differentiation is desired, the cells can be replated in 
culture dishes in, for example, serum-free basal medium 
20 Eagle (BME), which contains Earle's salt and L-glutamine. 
The cells can be cultured for about 5 days in the absence of 
FGF-2, EGF or other extrinsic differentiation factors. When 
induced to differentiate in this way, these cultured MNSCs 
exhibit characteristic morphologies of neurons or astrocytes 
25 when immunohistochemically stained with b-III tubulin (a 
neuronal cell marker) or glial fibrillary acidic protein (GFAP, 
an astrocyte marker). 
MSCs prepared according to the methods of Apps. 1 or 2 
and utilized in this invention that are proliferated in serum-
30 free media are grown in the presence of a substituted deox-
yuridine. Examples include a halo-deoxyuridine such as bro-
modeoxyuridine (BrdU) or iododeoxyuridine (IrdU), or an 
alkyl-substituted deoxyuridine such as a methyldeoxyuridine 
prior to transplantation into a host. The growth medium used 
35 to generate MSCs according to Apps. 1 and 2 for use in the 
present invention comprises the components of the long-term 
propagation media, but also contains an effective amount of 
substituted deoxyuridine, for example, concentrations 
between about 10 nanomolar and 100 micromolar, more pref-
40 erably between about 2 and 50 micromolar, and more prefer-
ably about 10 micromolar bromodeoxyuridine. Pre-trans-
plantation propagation can extend for an effective period, for 
example, between about 1 and 10 days, more preferably 
between about 1 and 5 days and more preferably between 
45 about 2 and 3 days. 
MSCs prepared according to the methods of Apps. 1 and 2 
can be administered according to the instant invention to an 
animal with abnormal or degenerative symptoms obtained in 
any manner, including those obtained as a result of age, physi-
50 cal or biological trauma, or neurodegenerative disease and the 
like, or animal models created by man using recombinant 
genetic techniques, such as transgenic and "gene knockout" 
animals. 
Recipients of the MSCs and pyrimidine derivatives accord-
55 ing to the methods of the invention can be immunosup-
pressed, either through the use of immunosuppressive drugs 
such as cyclosporin, or through local immunosuppression 
strategies employing locally applied immunosuppressants, 
but such immunosuppression need not necessarily be a pre-
60 requisite in certain immunoprivileged tissues such as, for 
example, brain and eye tissues or in the case of autologous 
transplantation. In certain embodiments, the delivery method 
of the invention can cause less localized tissue damage to the 
site of cell damage or malfunction than existing methods of 
65 delivery. 
MSCs of Apps. 1 and 2 and used herein can be prepared 
from the recipient's own tissue. In such instances, the prog-
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eny of the more developmentally potent cells can be gener-
ated from dissociated or isolated tissue and proliferated in 
vitro using the methods described in App. 1, App. 2, and 
herein. In the case of mesenchymal stem cells (MeSCs ), 
progeny can be generated from MeSCs isolated from, for 
example, bone marrow. Upon suitable expansion of cell num-
bers, the stem cells of Apps. 1 or 2 can be treated and admin-
istered according to the instant invention into the recipient's 
affected tissue. 
18 
lineage clusters of cells known as "neurospheres," can cause 
immediate senescence and increase the vulnerability ofNSCs 
in culture. See, e.g., Svendsen et al., 1998, J. Neurosci. Meth-
ods 85: 141-152.As provided by this invention, intraventricu-
lar transplantation provides an alternative route to site-spe-
cific injection disclosed in the prior art.Using intraventricular 
transplantation, grafted cells can gain access to various struc-
tures by the flow of cerebrospinal fluid (CSF), and transplan-
tation of NSCs prepared according to Apps. 1 and 2 or the 
It is well recognized in the art that transplantation of tissue 
into the CNS offers the potential for treatment of neurode-
generative disorders and CNS damage due to injury. Trans-
plantation of new cells into the damaged CNS has the poten-
tial to repair damaged circmtnes and provide 
neurotransmitters thereby restoring neurological function. It 
is also recognized in the art that transplantation into other 
tissue, such as eye tissue, offers the potential for treatment of 
degenerative disorders and tissue damage due to injury. Apps. 
10 present invention and administered according to the present 
invention in cluster form can act to prevent premature differ-
entiation at inappropriate anatomical sites in the brain and 
central nervous system. Regarding the eye, intraocular 
administration of clusters of NSCs prepared according to 
15 Apps. 1 and 2 or the present invention, for example into the 
vitreous fluid, allows these multi potent cells to migrate to the 
area of degeneration or injury and differentiate appropriately. 
Delivery of MSCs of Apps. 1 and 2 and of the present 
invention into other, non-immunoprivileged tissues can also 
20 be carried out, particularly when the MSCs are autologous to 
the recipient. 
1 and 2 provide methods for generating more developmen-
tally potent MSCs from less developmentally potent MSCs. 
The use of the cells of Apps. 1 or 2, or the cells of the instant 
invention specially stimulated for proliferation, migration or 
both in the treatment of neurological disorders and CNS 
damage, as well as the use of these MSCs in the treatment of 
other tissue damage or degeneration, can be demonstrated by 25 
the use of established animal models known in the art. 
There are significant differences in the method of delivery 
Functional integration of the graft into the host's neural 
tissue can be assessed by examining the effectiveness of 
grafts on restoring various functions, including but not lim-
ited to tests for endocrine, motor, cognitive and sensory func-
tions. Useful motor tests include tests that quantitate rota-
tional movement away from the degenerated side of the brain, 
and tests that quantitate slowness of movement, balance, 
to the brain and spinal cord of the cells prepared according to 
Apps. 1, 2 and the present invention, as well as the pyrimidine 
derivatives described herein, compared to the prior art. One 
exemplary difference is that the cells prepared according to 
Apps. 1, 2 and the present invention are transplanted intra-
ventricularly. Further, while the transplantation of one or 
more separate more cells of Apps. 1, 2 or the instant invention 
30 coordination, akinesia or lack of movement, rigidity and 
tremors. Cognitive tests include tests of the ability to perform 
everyday tasks, as well as various memory tests, including 
maze performance such as the Morris water maze perfor-
mance. For example, using the cells and methods of Apps. 1 
35 and 2, MNSCs injected into the ventricle of24-month-oldrats 
after in vitro expansion displayed extensive and positional 
incorporation into the aged host brain with improvement of 
cognitive score (FIG. 1), as assessed by the Morris water 
maze after 4 weeks of the transplantation. Results of the 
is efficacious, such cells are preferably transplanted in the 
form of clusters of two or more cells via a surgical procedure, 
injection using a syringe large enough to leave the neuro-
sphere-like clusters substantially intact, or insertion by cath-
eter. The results disclosed in the examples below indicate that 
ventricular delivery of the cells of Apps. 1 or 2 or the cells of 
the present invention in cluster form can result in migration to 
the area of damage in the brain and proper neuronal differen-
tiation. Further exemplified below is the effect of a pyrimi-
dine derivative on the stimulation of proliferation and migra-
tion. Another benefit ofintraventricular injection is less tissue 45 
destruction, resulting in less localized recruitment of immune 
cells by the host. This is evidenced by the lack of ventricular 
distortion, tumor formation, and increased host astrocyte 
staining without any immunosuppression. 
40 experiments disclosed herein indicate that the aged brain is 
capable of providing the necessary environment for MSCs of 
Apps. 1 and 2 and the present invention to retain their multi-
potent status and demonstrate the potential for neuroreplace-
ment therapies in age associated neurodegenerative disease. 
Functional integration of the graft into the host's other 
tissue can be assessed by examining the effectiveness of 
grafts on restoring various functions specific to the injured or 
degenerated tissue, for example improvement in sight for 
transplantation of stem cells of the invention to the eye.Using 
50 the methods of the present invention, substantial stimulation 
of proliferation of endogenous stem cells can be observed in 
the eye with administration of a pyrimidine derivative as 
disclosed herein. 
The method of delivery of the cells of Apps. 1, 2 or the 
instant invention to the brain can be essentially duplicated for 
other immunoprivileged tissue such as, for example, the eye. 
Delivery of intact clusters of two or more cells via injection 
using a syringe large enough to leave the clusters substan-
tially intact can result in migration to the area of damage in the 55 
eye and proper tissue-specific differentiation. Further, admin-
istration of pyrimidine derivatives according to the methods 
of the invention can substantially increase the proliferation of 
endogenous and exogenous MSCs. 
There are examples in the art of intra-tissue injection 60 
(brain) of dissociated and partially differentiated NSCs (see, 
e.g., Benninger et al., 2000, Brain Pathol. 10: 330-341; 
Blakemore et al., 2000, Cell Transplant. 9: 289-294; Rosser et 
al., 2000, Eur. J. Neurosci. 12: 2405-2413; Rubio et al., 2000, 
Mal. Cell. Neurosci. 16: 1-13). In contrast, the methods of the 65 
instant invention employ injection of generally intact clusters 
because the dissociation of clusters, in the case of neural-
As assessed by the Morris water maze test, improvement in 
spatial memory of MSC-transplanted animals (which cells 
were prepared according to Apps. 1 or 2, and apply to the cells 
of the instant invention) was accompanied by incorporation 
of the MSCs into the brain areas known to be related to spatial 
memory. The post-transplant morphology of rat brain tissue 
indicates that functional association of the transplanted cells 
to the host brain occurs. Immunohistochemical analysis 
revealed that the bIII-tubulin-positive donor-derived cells 
found in the cerebral cortex are characterized by having den-
drites pointing to the edge of the cortex whereas in the hip-
pocampus, donor-derived neurons exhibited morphologies 
with multiple processes and branches. These differential mor-
phologies of the transplanted MSCs in different brain regions 
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indicate that site-specific differentiation of the MSCs occurs 
according to various factors present in each brain region. 
Strong astrocyte staining was also found in the frontal 
cortex layer 3 and CA2 region ofhippocampus in rat brains 
transplanted with MSCs of Apps. 1 and 2, areas where astro-
cytes are not normally present in the animal. Migration of the 
more developmentally potent cells to the CA2 is of particular 
interest because CA2 pyramidal neurons highly express 
bFGF, and the expression ofbFGF is up-regulated by entorhi-
nal cortex lesions (see, e.g., Eckenstein et al., 1994, Biochem. 
Pharmacol. 47: 103-110; Gonzalez et al., 1995, Brain Res. 
701: 201-226; Williams et al., 1996, J. Comp. Neural. 370: 
147-158). CA2 pyramidal neurons in the host brain can 
express bFGF as a response to a reduction of synaptic trans-
mission, an event that can occur during aging. Subsequently, 
this expressed bFGF can act as a signal for transplanted MSCs 
of Apps. 1 and 2 or the present invention to respond, migrate 
or proliferate under the influence of bFGF produced in the 
host brain after the transplantation. 
20 
depending on the source and severity of the trauma. The term 
"biological trauma" denotes any acute brain injury that has its 
origin in a biological process, for example, stroke, aneurysm, 
epilepsy, brain tumor, hypoxia and the like. 
Another source of impaired or improper brain function is 
neurodegenerative disease. In recent years neurodegenerative 
disease has become an important concern due to an expanding 
elderly population that is at greatest risk for these disorders. 
Neurodegenerative diseases include, but are not limited 
10 Alzheimer's disease, amyotrophic lateral sclerosis (ALS), 
Parkinson's disease, Pick's disease, Huntington's disease, 
progressive supranuclear palsy, corticobasal degeneration, 
Parkinson-ALS-dementia complex, Gerstmann-Straussler-
Scheinker syndrome, Hallervorden-Spatz disease, Kufs' dis-
15 ease, Wilson's disease, multiple sclerosis (MS), late-onset 
metachromatic leukodystrophy and adrenoleukodystrophy. 
The effects of these diseases can be counteracted by admin-
istration of the MSCs of Apps. 1 and 2 and the present inven-
tion. 
The regions rich in astrocyte staining in transplanted rat 20 
brains are the same regions where extensively stained neu-
ronal fibers were identified (FIGS. 2a, 2d and 2e). During 
development, glial cells have many complex functions, such 
There are a variety of organic brain diseases that impair 
motor or cognitive function. Degeneration in the basal gan-
glia can lead to diseases with cognitive and motor symptoms, 
depending on the exact location of the degeneration. Motor 
deficits are a common result of degeneration in the basal 
ganglia. Huntington's chorea is associated with the degenera-
tion of neurons in the striatum, which leads to involuntary 
as neuronal and axonal guidance and production of trophic 
factors (see, e.g., Pundt et al., 1995, Brain Res. 695: 25-36). 25 
This overlapping distribution of glial and neuronal fibers 
strongly suggests that this interaction plays a pivotal role in 
survival, migration, and differentiation of the transplanted 
MSCs. 
jerking movements in the host. Degeneration of a small 
region called the subthalamic nucleus is associated with vio-
lent flinging movements of the extremities in a condition 
Immunohistochemistry of transplanted rat brains reveals a 
symmetrical distribution of neurons and astrocytes at both 
sides of the host brain, indicating that the progeny of the more 
developmentally potent cells of Apps. 1, 2 (and those of the 
present invention) can migrate. Although astrocytes have 
been shown to migrate over long distances following trans-
plantation (see, e.g., Blakemore et al., 1991, Trends Neurosci. 
14: 323-327; Hatton et al., 1992, Glia 5: 251-258; Lundberg 
et al., 1996, Exp. Neural. 139: 39-53), there is experimental 
evidence showing that neurons do not migrate as widely as 
glial cells (see, e.g., Fricker et al., 1999, J. Neurosci. 19: 
5990-6005). As disclosed herein, cells derived from the 
MSCs of Apps. 1 and 2 possess similar migratory capacity to 
astrocyte precursors. 
30 called ballismus, while degeneration in the putamen and glo-
bus pallidus is associated with a condition of slow writhing 
movements or athetosis. In Parkinson's disease, degeneration 
is seen in another area of the basal ganglia, the substantia 
nigra par compacta. This area normally sends dopaminergic 
35 connections to the dorsal striatum, which are important in 
regulating movement. Therapy for Parkinson's disease has 
centered upon restoring dopaminergic activity to this circuit, 
which can be accomplished by transplantation of neural stem 
cells to this region of the brain according to the instant inven-
40 tion 
As MSCs of Apps. 1 and 2 and the present invention can 
mimic neural stem cells in many regards, relevant informa- 45 
ti on pertaining to neural stem cells is presented, followed by 
information pertaining to mesenchymal and retinal stem 
cells. One of skill in the art will readily recognize the methods 
In Alzheimer's disease, another neurodegenerative dis-
ease, there is substantial cellular degeneration of the forebrain 
and cerebral cortex. Further, a localized area of the basal 
ganglia, the nucleus basalis of Meynert, appears to be selec-
tively degenerated. This nucleus normally sends cholinergic 
projections to the cerebral cortex, which are thought to par-
ticipate in cognitive functions including memory. 
Mesenchymal Related of the invention are not limited to these three types of stem 
cells and instead extend to cover all cell types not yet termi- 50 
nally differentiated. 
Although adult stem cells continue to possess some multi-
potency, cell types produced from adult stem cells are limited 
by their tissue-specific character. For example, human NSCs 
spontaneously differentiate into brain cells under basal media 
conditions, but MeSCs cannot spontaneously differentiate 
Neural-Related 
Due to the generally low proliferation rate of mammalian 
NSCs, there is a correlation between advancing age and 
impaired brain function even in the absence of specific neu-
rodegenerative disease or physical or biological brain trauma. 
Apps. 1 and 2 and the present invention provide methods for 
counteracting impaired brain function due to advancing age 
through the addition of MSCs (of Apps. 1 and 2 and the 
present invention) capable of proliferation, migration and 
differentiation in mammalian brain when introduced thereto. 
Physical trauma and biological trauma are additional 
causes of impaired or improper brain function. The term 
"physical trauma" denotes brain cell damage due to external 
sources such as blunt head trauma, severe concussion and the 
like. Such physical trauma can be localized or general 
55 into neural cells without the addition of certain factors. These 
results indicate that each stem cell contains specific informa-
tion that would allow it to become a special type of cell, i.e., 
they are partially committed to become a particular type of 
cell in a tissue-specific manner. To overcome this barrier of 
60 stem cell lineage, alterations to the cells and their environ-
ment are necessary. However, the exact regulation mecha-
nisms of tissue-specific stem cell fate decisions remain 
unclear. The absence ofthis knowledge creates an important 
problem, because although MeSCs are rather easy to isolate 
65 from bone marrow and to proliferate in culture, they cannot 
naturally differentiate into NSCs or other non-mesenchymal-
lineage cells. Although the potential therapeutic use of 
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MeSCs in the central nervous system has been discussed, 
technologies to induce neural lineage in MeSCs had not been 
fully established prior to Apps. 1 and 2. The present invention 
provides methods stimulating proliferation, migration or both 
proliferation and migration of the endogenous stem cell 
population or populations of exogenously introduced cells, 
such as, for example, the cells of Apps. 1 or 2. 
22 
MeSCs prepared according to the methods of App. 1 can 
serve as an alternative to NSCs for potential therapeutic use 
utilizing the methods of App. 1 and the present invention, 
which exploit the capacity of substituted deoxyuridine spe-
cies, such as BrdU, to prime the MeSCs, i.e., remove them 
from their restricted mesenchymal differentiation path to the 
neural stem cell-like (or other lineage, i.e., make them more 
developmentally potent) differentiation path and pyrimidine 15 
derivatives, which stimulate them to proliferate and migrate 
mented media condition, NSCs spontaneously differentiated 
into bIII-tubulin-, glial fibrillary acidic protein (GFAP)-, and 
04-immunopositive cells, markers for neurons, astrocytes, 
and oligodendrocytes, respectively. MSCs treated according 
to methods of Apps. 1 and 2 migrate and differentiate into 
neurons and glia after transplantation into the brains of 
24-month-old rats and significantly improved the cognitive 
functions of these animals. This result suggested that MSCs 
produced according to Apps. 1 and 2 could provide trans-
lO plantable material to produce a retinal stem cell alternative. 
far above wild-type rates. MeSCs were successfully differen-
tiated into neurons and glia in vitro and in vivo using the 
substituted deoxyuridine pretreatment of App. 1. Thus, 
MeSCs of App. 1 can serve as an alternative to NSCs for 20 
potential therapeutic use in neuroreplacement utilizing the 
methods of App. 1 and the present invention. 
There are variety of factors involved in the development of 
retinal tissue that regulate the proliferation and differentiation 
of retinal cells. Transforming growth factor beta 3 (TGF-b3) 
is thought to regulate cell proliferation during development 
and also influence the commitment or the differentiation, or 
both, of neural progenitor cells to retinal fates. Treatment of 
embryonic day-18 rat retinal cultures with TGF beta-like 
protein, activinA, causes the progenitor cells in these cultures 
to exit the cell cycle and differentiate into rod photoreceptors, 
indicating that the TGF family is an important regulator of 
photoreceptor differentiation in the developing retina. Treat-
ment of the NSCs prepared according to Apps. 1 and 2 can be 
induced to adopt a retinal differentiation path through expo-
sure to the above factors. Utilizing the methods and reagents 
of the present invention, both exogenous MSCs, like those 
The methods of the instant invention are important in the 
neuroreplacement field because they enable the expansion of 
endogenous stem cell numbers in vivo. Further, the methods 25 
of the invention are important in the neuroreplacement field 
because they enable the stimulation of proliferation and 
migration in exogenously introduced, developmentally 
potent, stem cell populations such as those of Apps. 1 or 2. 
Since the pyrimidine derivative, as used in the instant inven- 30 
tion, can be used on various stem cell populations, the inven-
tion is not only useful to neuroreplacement but to other kinds 
prepared according to Apps. 1 and 2, and endogenous stem 
cells of the eye can be stimulated to proliferate and migrate 
beyond wild-type levels. 
Previous transplantation studies ofNSCs into retinal tissue 
with rd mice (a model of retinitis pigmentosa), mechanical 
lesions, transient ischemia and normal retina have revealed 
that donor cells migrate into the retinal area and differentiate of tissue regeneration or replacement as well. 
Retinal Related 
Retinal degenerative diseases, including macular degen-
eration, are major causes of blindness. Despite investigations 
into gene therapy, growth/survival factor injections and vita-
min treatments, no effective vision-restoring treatments are 
currently available. Visual impairment caused by the degen-
eration of photoreceptors or neural cells has been considered 
incurable because of a long-held "truism" that neurons do not 
regenerate during adulthood. However, this statement has 
been challenged and there is new evidence that these cells do 
indeed have the potential to be renewed after maturation, thus 
opening a door for the development of novel therapies to treat 
visual impairment by retinal regeneration using stem cell 
transplantation. 
The capacity for retinal regeneration in cold-blooded ver-
tebrates has long been recognized. Fish and amphibians con-
tinue to make new retinal neurons through a population of 
retinal stem cells residing at the peripheral margin of the 
retina, the so-called "ciliary marginal zone." Recent studies 
have provided evidence that birds and adult mammals also 
possess a zone of cells at the retinal margin analogous to the 
ciliary marginal zone of cold-blooded vertebrates. These reti-
nal stem cells are reported not only to generate photoreceptor 
and other retinal cells in vitro, but also to differentiate into 
retinal cells following transplantation into the retinal area. 
Although these results indicate the possibility of retinal 
regeneration therapy, an alternative source of stem cells, or a 
means to increase the number of endogenous retinal stem 
cells, is required for clinical applications because the number 
of retinal stem cells is limited. 
35 into neurons and glia, but they did not show any retinal cell 
markers. These results indicated that NSCs are already com-
mitted to become neural tissue, and that this commitment is 
not mutable solely by transplantation into the retina. Thus, to 
differentiate NSCs (or cells of alternate origin, such as 
40 MeSCs) into retinal cells, alteration of their epigenetic infor-
mation before retinal transplantation appeared necessary, 
something accomplished by the methods of Apps. 1 and 2. 
Using the methods of Apps. 1 and 2, NSCs or easily obtain-
able MeSCs, i.e., can be transformed into MSCs and subse-
45 quently used as alternatives to retinal stem cells to repair 
ocular tissue damage or promote tissue regeneration. Treat-
ment of endogenous multipotent stem cells populations in 
vivo or the multipotent stem cells of Apps. 1 or 2 in vitro 
according to the methods of the present invention, can 
50 enhance their number and/or migration and hence increase 
their efficacy in repairing damaged tissue in the eye. 
The inventive methods of Apps. 1 and 2 use BrdU and other 
substituted deoxyuridines to change the cell fate decisions of 
stem cells. In the case ofretinal transplants, these MSCs are 
55 treated with TGF-b3 to encourage their commitment change 
into the various cell types found in eye tissue, inter alia, 
chorid, Buchs and retinal pigment epithelium cells, rod and 
cone photoreceptor cells, horizontal cells, bipolar neurons, 
amacrine, ganglion and optic nerve cells. These non-limiting, 
60 exemplary cell types found in eye tissue are collectively 
referred to as retinal cells. These results are enhanced by the 
methods of the present invention wherein the number of 
MSCs competent to migrate and differentiate appropriately is 
increased due to stimulated proliferation. 
Neural stem cells have been isolated from embryonic and 65 
adult mammalian brains and have been propagated in vitro in 
There are a variety of neurological and corporal deficits 
that can be addressed using the MSCs ofApps. 1 and 2 and the 
a variety of culture systems. Using a serum-free unsupple- present invention. 
US 7,687,505 B2 
23 
"Neurological Deficits" Amenable to Treatment 
Because the invention relates in part to the discovery that 
multipotent precursor cells can be stimulated to proliferate 
and migrate through the brain and other tissues, such MSCs 
can be used to treat neurological deficits caused by a wide 
variety of diseases, disorders, and injuries. These insults 
include, but are not limited to, the following. 
Degenerative Diseases 
24 
(wet or dry), post-surgical healing, tumor, heritable retinal 
dystrophies, optic nerve atrophy, and other retinal degenera-
tive diseases. Cells targeted for repair utilizing cells and 
methods of the invention include, for example, choroids, 
Buchs, retinal pigment epithelial (RPE), rods, cones, horizon-
tal cells, bipolar neurons, amacrine, ganglion, and optic 
nerve. 
Injuries and Diseases of the Spinal Cord 
Degenerative diseases that can be treated according to the 
methods of the invention include Alzheimer's disease (AD), 
Parkinson's disease (PD), Huntington's disease (HD), Pick's 
disease, progressive supranuclear palsy (PSP), striatonigral 
degeneration, cortico-basal degeneration, childhood disinte-
grative disorder, olivopontocerebellar atrophy (OPCA; 
including a heritable form), Leigh's disease, infantile necro-
tizing encephalomyelopathy, Hunter's disease, muco-
polysaccharidosis, various leukodystrophies (such as 
Krabbe's disease, Pelizaeus-Merzbacher disease, and the 
like), amaurotic (familial) idiocy, Kuf's disease, Spielmayer- 20 
Vogt disease, Tay Sachs disease, Batten disease, Jansky-
Bielschowsky disease, Reye's disease, cerebral ataxia, 
chronic alcoholism, beriberi, Hallervorden-Spatz syndrome, 
and cerebellar degeneration. 
10 
Injuries to or diseases affecting the spinal cord can also be 
treated according to the methods of the invention. Such inju-
ries or diseases include post-polio syndrome, amyotrophic 
lateral sclerosis, nonspecified spinal degeneration, traumatic 
injury (such as those caused by automobile or sporting acci-
15 dents), including any injury that crushes, partially severs, 
completely severs, or otherwise adversely affects the function 
of cells in the spinal cord), injuries caused by surgery to the 
spinal cord (e.g., to remove a tumor), anterior horn cell dis-
ease, and paralytic diseases. 
Demyelinating or Autoimmune Disorders 
Neurological deficits caused by demyelination or an 
autoimmune response can be treated according to the meth-
ods of the invention. Such deficits can be caused by multiple 
sclerosis, or lupus. 
Traumatic and Neurotoxic Injuries to the Central Nervous 25 
System 
Infectious or Inflammatory Diseases 
Neurological deficits caused by an infection or inflamma-
tory disease can be treated according to the methods of the 
invention. Infections or inflammatory diseases that can cause 
treatable deficits include Creutzfeldt-Jacob disease and other 
slow virus infectious diseases, AIDS encephalopathy, post-
encephalitic Parkinsonism, viral encephalitis, bacterial men-
Traumatic and neurotoxic injuries that can be treated 
according to the methods of the invention include gunshot 
wounds, injuries caused by blunt force, injuries caused by 
penetration injuries (e.g., stab wounds), injuries caused in the 30 
course of a surgical procedure (e.g., to remove a tumor or 
abscess from the CNS or to treat epilepsy), poisoning (e.g., 
with MPTP or carbon monoxide), shaken-baby syndrome, 
adverse reactions to medication (including idiosyncratic 
reactions), drug overdose (e.g., from amphetamines), and 35 
post-traumatic encephalopathy. 
ingitis and meningitis caused by other organisms, phlebitis 
and thrombophlebitis ofintracranial venous sinuses syphilitic 
Parkinsonism, and tuberculosis of the CNS. 
In addition to the deficits, diseases and disorders set forth 
explicitly above, those of ordinary skill in the art are well able 
to recognize neurological deficits, regardless of their cause, 
and to apply the methods of the present invention to treat 
Ischemia 
Any disruption of blood flow or oxygen delivery to the 
nervous system can injure or kill cells, including neurons and 
glial cells, therein. These injuries can be treated according to 
the methods of the present invention and include injuries 
caused by a stroke (including a global stroke (as may result 
from cardiac arrest, arrhythmia, or myocardial infarction) or 
a focal stroke (as may result from a thrombus, embolus, 
hemorrhage, or other arterial blockage)), anoxia, hypoxia, 
partial drowning, myoclonus, severe smoke inhalation, dys-
tonias (including heritable dystonias ), and acquired hydro-
cephalus. 
Developmental Disorders 
Developmental disorders that can be treated according to 
the methods of the invention include schizophrenia, certain 
forms of severe mental retardation, cerebral palsy (whether 
caused by infection, anoxia, premature birth, blood type 
incompatibility: etc. and whether manifest as blindness, deaf-
ness, retardation, motor skill deficit, etc.), congenital hydro-
cephalus, metabolic disorders affecting the CNS, severe 
autism, Down Syndrome, LHRH/hypothalamic disorder, and 
spina bifida. 
Disorders Affecting Vision 
Disorders affecting vision, particularly those caused by the 
loss or failure of retinal cells, can be treated according to the 
methods and cells of the invention. These disorders include, 
for example, diabetic retinopathy, serious retinal detachment, 
retinal damage associated with glaucoma, traumatic injury to 
the retina, retinal vascular occlusion, macular degeneration 
40 
patients who have such deficits. In addition to the conditions 
listed above, that are amenable to treatment with the methods 
described herein, neurological deficits can be caused by 
Lesch-Nyhan syndrome, myasthenia gravis, various demen-
tias, numerous parasitic diseases, and epilepsy. Further, alle-
45 viation of age-related memory loss is an object of the inven-
tion. The methods of the invention can be readily applied to 
alleviate neurological deficits caused by these and other dis-
eases, disorders, or injuries. 
50 
"Corporal Deficits" Amenable to Treatment 
The invention also relates to the amelioration of corporal 
deficits utilizing multipotent precursor cells stimulated to 
divide, migrate through damaged tissue and differentiate in a 
tissue-specific manner. Cells according to the invention can 
be used to treat corporal deficits caused by a wide variety of 
55 diseases, disorders, and injuries, the result of which is trauma, 
malfunction, degeneration or loss of muscle such as, for 
example, cardiac muscle due to myocardial infarction. Other 
examples include malfunction, degeneration or loss of other 
cells and tissues apart from those discussed in the neurologi-
60 cal deficit section above such as, for example, internal organs. 
For example, liver function can be adversely affected by, 
among other things, disease (e.g., cirrhosis or hepatitis), 
trauma or age. Other exemplary internal organs amenable to 
treatment utilizing the embodiments of the invention include 
65 heart, pancreas, kidney, stomach, and lung. Corporal deficits 
also comprise malfunction, degeneration or loss of skeletal 
assets such as, for example, vertebrae. 
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An advantage of the cells of the invention is that they can be 
genetically engineered according to routine procedures 
known in the art (See, e.g., Sambrook et al., 2001, MOLECU-
LAR CLONING: A LABORATORY MANUAL. 3rd ed., 
Cold Spring Harbor Laboratory Press: N.Y.). In certain 
embodiments, constructs encoding proteins of interest can be 
provided to the cells. In other embodiments, constructs that 
inhibit expression of undesired proteins can be provided 
(such as, for example, ribozymes and antisense molecules). In 
further embodiments, drug resistance genes and markers, or 10 
detectable markers such as GFP can be provided. Preferably, 
the marker and other genes are operably and genetically 
linked to gene expression regulatory elements (including but 
not limited to promoters and enhancers) that are operable in a 
terminally differentiated cell derived from the MNSCs of the 15 
invention or in the undifferentiated MNSCs of the invention 
or both. 
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These behavioral results indicate the beneficial effects of 
the transplantation ofBrdU-treated human NSCs into the host 
brain. After the second water maze task, postmortem brains 
were further analyzed by immunohistochemistry for human 
bIII-tubulin and human GFAP, markers for neurons and astro-
cytes respectively. There was no sign of ventricular distortion, 
no evidence of tumor formation, and no strong host anti-graft 
immunoreactivity was observed as revealed by weak host 
astrocyte staining. Intensely and extensively stained with 
bIII-tubulin, neurons with BrdU-positive nuclei were found 
in bilateral singular and parietal cortexes (FIG. 2a-c) and 
hippocampus (FIG. 2d,e). The bIII-tubulin-positive neurons 
found in the cerebral cortex were typified by a dendrite point-
ing to the edge of the cortex. In the hippocampus, donor-
derived neurons exhibited multiple morphologies, varying in 
cellular size and shape, and one or more processes and 
branching. 
Generally, GFAP-positive astrocytes were localized near 
the area where neuronal cells were found. On further analysis 
The following examples are presented in order to more 
fully illustrate the preferred embodiments of the invention. 
They should in no way be construed, however, as limiting the 
scope of the invention, as defined by the appended claims. 
EXAMPLES 
Example 1 
20 (overlapping images of their distributions), donor-derived 
astrocytes were found to co-localize with neuronal fibers in 
the cortex (FIG. 2j). These astrocytes were larger than the host 
glia, with cell bodies 8-10 microns in diameter and thick 
processes. Some of these astrocytes had a unilateral morphol-
Improvement of Cognitive Function in Aged Rat by the 
Transplantation ofNSCs of the Invention 
25 ogy (asymmetric), and the immunostaining formed a thin ring 
around the nucleus, while the majority of the processes were 
formed on the other side. Most cells appeared a symmetrical 
with processes forming from all sides. The absence of this 
type of cell in normal animal without the transplantation of Human NSCs do not require any exogenous factors for 
differentiation and survived more than three weeks in basal 
media without the addition of any factor to support their 
survival (Qu et al., 2001, Neuroreport 12: 1127-32). Thus, it 
appears that human NSCs produce factors to differentiate and 
support themselves, which suggested that these cells could be 
transplanted into aged animals after treatment according to 35 
the methods of Apps. 1, 2 and the present invention. 
30 treated human NSCs was confirmed using immunohis-
tochemistry for rat astrocytes. Host astrocytes had small cell 
bodies with multiple delicate processes, and were distributed 
throughout the brain mainly in white matter and around the 
Human NSCs, expanded without differentiation under the 
influence of mitogenic factors in supplemented serum-free 
media and pretreated by the incorporation ofbromodeoxyuri-
dine (BrdU) into the nuclear DNA, were injected into the 40 
lateral ventricle of mature (6-month-old) and aged (24-
month-old) rats. Human NSCs prepared according to the 
methods of the invention survived 30 days after xenotrans-
plantation into aged rat brain, while retaining both multipo-
tency and migratory capacity, and also improved cognitive 45 
function in 24-month-old rats. Cognitive function of the ani-
mals was assessed by the Morris water maze both before and 
four weeks after the transplantation of human NSCs of the 
invention. Before human NSC transplantation, some aged 
animals (aged memory unimpaired animals) cognitively 50 
functioned in the range of mature animals, while others (aged 
memory impaired animals) functioned entirely out of the 
cognitive range of the mature animals. After transplantation 
of the BrdU-treated human NSCs, most aged animals had 
cognitive function in the range of the mature animals. Strik- 55 
ingly, one of the aged memory-impaired animals showed 
dramatic improvement in its behavior, functioning even better 
than the mature animals (FIG. la). Statistical analysis showed 
that cognitive function was significantly improved in both 
mature and aged memory impaired animals but not in aged 60 
memory-unimpaired animals after BrdU-treated human NSC 
transplantation (FIG. lb), which may be due to the physical 
limitations of the aged animals. The performance of three of 
the aged animals deteriorated in the water maze after trans-
plantation of treated human NSCs. It is possible that the 65 
physical strength of these animals deteriorated during the 
experimental period. 
edges of the brain. 
These results demonstrated that transplanted cells of Apps. 
1 and 2 migrated in rat brain and differentiated into appropri-
ate cell types. The concomitant improvement in cognitive 
function indicated that transplanted MSCs of Apps. 1 and 2 
were functionally integrated into the recipient brains. 
The Morris Water Maze: 
The Morris water maze consists of a large circular tank 
(diameter, 183 cm, wall height, 58 cm), filled with water (27° 
C.) and opacified by the addition of powdered milk (0.9 kg). 
Beneath the water surface (1 cm) nearthe center of one of the 
four quadrants of the maze a clear escape platform (height, 
34.5 cm) is positioned. The rats receive three training trials 
per day for seven consecutive days, using a 60 sec inter-trial 
interval. A training trial consists of placing the animal in the 
water for 90 seconds or until the swimming rat successfully 
locates the platform. If the rat fails to find the platform within 
the 90 seconds, the animal is gently guided to the platform. 
For spatial learning assessment, the platform's location 
remains constant in one quadrant of the maze, but the starting 
position for each trial is varied. Every sixth trial is a probe 
trial, during which the platform is retracted to the bottom of 
the pool for 30 sec and then raised and made available for 
escape. The training trials assess the acquisition and day-to-
day retention of the spatial task while the probe tests are used 
to assess search strategy. At the completion of a spatial learn-
ing assessment, one session with six trials of cue training is 
performed Rats are trained to escape to a visible black plat-
form that is raised 2 cm above the surface of the water. The 
location of the platform is varied from trial to trial to assess 
sensorimotor and motivational functioning independent of 
spatial learning ability. Each rat is given 30 seconds to reach 
the platform and is allowed to remain there briefly before the 
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30 second inter-trial interval. Accuracy of performance is 
assessed using a learning index score computed from the 
probe trials. The learning index is a derived measure from 
average proximity (cumulative search error divided by the 
length of the probe trial) on the second, third, and fourth 5 
interpolated probe trials. Scores from these trials are 
weighted and summed to provide an overall measure of spa-
tial learning ability. Lower scores on the index indicate a more 
accurate search near the target location; higher scores indicate 
mouse IgGl monoclonal anti-GFAP, clone G-A-5 (1:500, 
Sigma), respectively, overnight at 48° C. in the dark. After 
brief washing with PBS to remove excess primary antibody, 
the location of primary antibody binding was then determined 
using FITC-conjugated (Jackson IR Laboratories, Inc.) sec-
ondary antibody (donkey anti-mouse (1:200) or donkey anti-
goat IgG (H+L; 1:200), respectively) by incubating the sec-
tions for 2 hours at room temperature in the dark. 
The sections were then washed with PBS thoroughly 
a more random search and poor learning. 
Cell Migration and Differentiation: 
In order to investigate differentiation and/or migration of 
the cells of Apps. 1 or 2 in the brain, MSCs of those applica-
tions were transplanted into rodent brain. The animals were 
anesthetized with 50 mg/kg pentobarbital (i.p.) and mounted 
10 
before mounting to glass slides. The mounted sections were 
covered with Vectashield using 4',6-diamidine-2-
phenylindole.2HC1 (DAPI, Vector Laboratories, Inc., Burlin-
game, Calif.) for fluorescent microscopic observation. Micro-
15 scopic images were taken by using anAxiocam digital camera 
mounted on the Axioscope 2 with Axiovision software 
(Zeiss). in a stereotaxic apparatus (David Kopf). Approximately 
lxl04 to lxl05 cells in 5 µl phosphate-buffered saline were 
injected into the ventricle using a micro syringe attached to the 
stereotaxic apparatus. After removing the hair from the sur- 20 
gical site using electric razor, an iodine swab was be applied 
NSC Culture: 
NSCs were purchased (Bio Whittaker, Walkersville, Md.), 
and alternatively isolated from human tissue, and cultured in 
a nonsupplemented, serum-free basal medium comprising 
HAMS-F12 (Gibco, BRL, Burlington, ON); antibiotic-anti-
mycotic mixture (1:100, Gibco); B27 (1:50, Gibco); human 
to the area and a 0.5 cm surgical incision was made caudal to 
rostral in the skin at the surface of the cranium. The ventricle 
was stereotaxically localized using the following exemplary 
coordinates: AP=-0.58 mm from bregma, ML=+l mm, and 
2.4 mm below dura (for mouse): AP=-1.4 mm from bregma, 
ML=+3.3 mm, and 4.5 mm below dura (for rat). A 0.4-mm 
hole was made in the cranium by careful drilling. The cells of 
Apps. 1 or 2 were injected into the ventricle using a microsy-
ringe. The injection was delivered over a period of five min-
utes and the needle was left in place for an additional two 
minutes following the injection. After the injection, the sur-
gically incised skin was closed by Michel suture clip (2.5x 
1.75 mm). Ten days post-surgery, proper healing of the inci-
sion site was observed, and the Michel sutures were removed. 
The existence and location of the cells of Apps. 1 or 2 after 
administration in rat brain was analyzed as follows. At 30 
days post-transplantation, the rats were sacrificed by an over-
dose of sodium pentobarbital (70 mg/kg, i.p.) and perfused 
with phosphate buffered saline (PBS) followed by 4% 
paraformaldehyde. Brains were removed and incubated over-
night in 4% paraformaldehyde fixative containing 20% 
sucrose. The brains were sliced into 20 micron coronal sec-
tions using a cryomicrotome. The sections were washed 
briefly in PBS and pretreated with IM HCl for 30 minutes at 
room temperature and neutralized with sodium borate (0.1 M, 
pH 8.0) for 30 minutes in order to increase the accessibility of 
25 recombinant FGF-2 and EGF (20 ng/ml each, Rand D Sys-
tems, Minneapolis, Minn.) and heparin (5 ug/ml, Sigma, St. 
Louis, Mo.). The cells were incubated at about 3 7° C. in a 5% 
C02 humidified incubation chamber (Fisher, Pittsburgh, Pa.). 
To facilitate optimal growth conditions, NSC clusters were 
30 sectioned into quarters every 2 weeks and fed by replacing 
50% of the medium every 4-5 days. To inhibit differentiation, 
the cells can be propagated on an uncoated flask or a flask that 
has been treated to repel the cells. To induce differentiation, 
these cells can be replated in the culture dishes (about lxl05 
35 per dish) in the serum-free basal medium Eagle (BME), 
which comprises Earle's salt and L-glutamine, and cultured 
for about 5 days in the absence of FGF-2 and EGF and 
without the addition of other extrinsic differentiation factors. 
NSCs cultured in this serum-free medium can spontaneously 
40 undergo differentiation into neuronal cell types. 
Example 2 
45 Increase of Endogenous Stem Cell Proliferation by a Pyrimi-
dine Derivative 
To investigate the effect ofMS-818, a pyrimidine deriva-
an anti-BrdU antibody to BrdU incorporated in the cell 
nuclei. After rinsing with PBS, sections were transferred to 
absolution containing 0.25% Triton X-100 in PBS (PBST) for 50 
30 minutes. The sections were then blocked by incubation in 
PBST containing 3% donkey normal serum for 1 hour, fol-
lowed by incubating the sections overnight at 48° C. with 
sheep anti-BrdU ( 1: 1000; Jackson IR Laboratories, Inc. West 
Grove, Pa.) or mouse anti-BrdU (1 :200; DSHB, Iowa City, 55 
Iowa) diluted in PBST. After rinsing the sections in PBS, 
donkey anti-mouse or donkey anti-sheep conjugated to 
rhodamine IgG (Jackson IR Laboratories, Inc.) was added at 
tive, on stem cell population in vivo, MS-818 (3 mg/kg/day, 
i.p.) was injected for 5 days into aged (27-month old) male 
Fisher 344 rats. The same volume of saline was injected into 
control animals. Bromodeoxyuridine. (BrdU) (100 mg/kg/ 
day i.p.) was theninjectedfor3 days. Twenty-four hours after 
the last injection, the brains were removed and fixed for 
immunohistochemical detection of the proliferating cells by 
immunostaining for BrdU. The number ofBrdU positive cells 
increased more than seven fold in the cerebral cortices of 
MS-818-treated animals compared to those of controls (FIG. 
3a, b, e ), indicating an increased neural stem cell population in 
the brain. In the area of the subventricular zone, a significant a 1 :200 dilution in PBST and the sections further incubated 
for 2 hours at room temperature in the dark. 
The transplanted cells of Apps. 1 or 2, with BrdU immu-
nopositive nuclei, were stained for human bIII-tubulin and 
human glial filament protein (GFAP). The sections were then 
washed with PBS and incubated with mouse IgG2b mono-
clonal anti-human bIII-tubulin, clone SDL3D10 (1:500, 
Sigma), goat antihuman GFAP, N-terminal human affinity 
purified (1:200, Research Diagnostics Inc., Flander, N.J.) or 
60 increase not only in the proliferation but also in the migration 
of stem cells was found (FIG. 3c, d). When this compound was 
injected directly into the vitreous cavity (10 µg one time 
injection), a dramatic increase in the number of BrdU-posi-
tive cells was found in the retinal ciliary marginal zone (FIG. 
65 4) after three days. 
It should be understood that the foregoing disclosure 
emphasizes certain specific embodiments of the invention 
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and that all modifications or alternatives equivalent thereto 
are within the spirit and scope of the invention as set forth in 
the appended claims. 
What is claimed is: 
1. A method of stimulating proliferation, migration or both 
proliferation and migration of exogenous neural stem cells or 
retinal stem cells or both neural and retinal stem cells in vivo, 
the method comprising administering an effective amount of 
30 
formula (1) or (2), or a pharmaceutically acceptable salt 
thereof, for an effective period, 
(1) 
a pyrimidine derivative of formula (1) or (2), or a pharmaceu- 10 
tically acceptable salt thereof, for an effective period to a 
mammal that has had more developmentally potent cells 
administered thereto 
~-:~y() 
~ 
i5 /\ (2) 
(1) 
R,-:~y() 
~ 
(2) 
i5 /\ 
0
==<N-rNYN\___Jx 
RKYN 
Ri; R1 Rs 
wherein Rl to RS independently represent a hydrogen atom, 
a lower alkyl group, CH3 0CH2CH2-, CH2CONH2 , 
-COCH3 , --COC2 H5 or --CH2 0COC2H5 , and X repre-
sents NH, N-CH3 , N-C2H5 , N-ph, N-COOC2H5 , 
N-S02 CH3 , CH2 , CHCH3 , CHC2H5 , -0- or -S- in 
which ph stands for a phenyl group. 
2. The method of claim 1, wherein the method stimulates 
proliferation of exogenous mammalian stem cells in vivo. 
3. The method of claim 1, wherein the method stimulates 
migration of exogenous mammalian stem cells in vivo. 
4. The method of claim 1, wherein the method stimulates 
proliferation and migration of exogenous mammalian stem 
cells in vivo. 
5. A method of stimulating proliferation, migration or both 
proliferation and migration of mammalian neural stem cells 
or retinal stem cells or both neural and retinal stem cells in 
vitro, the method comprising contacting a mammalian stem 
cell with an effective amount of a pyrimidine derivative of 
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wherein Rl to RS independently represent a hydrogen atom, 
a lower alkyl group, CH30CH2 CH2-, CH2CONH2 , 
--COCH3 , --COC2 H5 or --CH2 0COC2 H5 , and X repre-
25 sents NH, N--CH3 , N-C2H5 , N-ph, N-COOC2H5 , 
N-S02 CH3 , CH2 , CHCH3 , CHC2 H5 , ---0- or -S- in 
which ph stands for a phenyl group. 
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6. The method of claim 5, wherein the method stimulates 
proliferation of mammalian stem cells in vitro. 
7. The method of claim 5, wherein the method stimulates 
migration of mammalian stem cells in vitro. 
8. The method of claim 5, wherein the method stimulates 
proliferation and migration of mammalian stem cells in vitro. 
9. The method of claim 5 further comprising the step of 
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administering a growth factor. 
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10. The method of claim 9 wherein the growth factor is 
fibroblast growth factor, epidermal growth factor or a combi-
nation thereof. 
11. The method of claim 9 where in the growth factor is a 
combination of fibroblast growth factor and epidermal 
growth factor. 
12. The method of claim 9 wherein the growth factor is 
fibroblast growth factor. 
13. The method of claim 9 wherein the growth factor is 
epidermal growth factor. 
14. The method of claim 5 further comprising the step of 
contacting the mammalian stem cell with heparin. 
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